Third Rock fund trims Rapport Therapeutics (RAPP) stake under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Third Rock Ventures V, L.P. reported an open-market sale of 133,618 shares of Rapport Therapeutics, Inc. common stock on May 11, 2026 at a weighted average price of $40.244 per share. The sale occurred in multiple trades between $40.00 and $40.665 per share under a previously adopted Rule 10b5-1 trading plan.
After this transaction, Third Rock Ventures V directly held 6,299,097 shares of Rapport Therapeutics common stock. A related fund, Third Rock Ventures VI, L.P., is reported as holding an additional 969,218 shares indirectly, with the general partner entities disclaiming beneficial ownership except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 133,618 shares ($5,377,323)
Net Sell
2 txns
Insider
Third Rock Ventures V, L.P., Third Rock Ventures GP V, LP, TRV GP V, LLC, Third Rock Ventures VI, L.P., Third Rock Ventures GP VI, L.P., TRV GP VI, LLC
Role
null | null | null | null | null | null
Sold
133,618 shs ($5.38M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 133,618 | $40.244 | $5.38M |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 6,299,097 shares (Direct, null);
Common Stock — 969,218 shares (Indirect, By Third Rock Ventures VI, L.P.)
Footnotes (1)
- The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 21, 2025, previously adopted by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). These shares are directly held by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. The shares are held directly by Third Rock Ventures VI, L.P. ("TRV VI"). The general partner of TRV VI is Third Rock Ventures GP VI, L.P. ("TRV GP VI"). The general partner of TRV GP VI is TRV GP VI, LLC ("TRV GP VI LLC"). Each of TRV GP VI, and TRV GP VI LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between any TRV V related parties and any TRV VI related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.
Key Figures
Shares sold: 133,618 shares
Weighted average sale price: $40.244 per share
Sale price range: $40.00–$40.665 per share
+3 more
6 metrics
Shares sold
133,618 shares
Open-market sale on May 11, 2026
Weighted average sale price
$40.244 per share
Common stock sale on May 11, 2026
Sale price range
$40.00–$40.665 per share
Multiple transactions in reported sale
Direct holdings after sale
6,299,097 shares
Third Rock Ventures V, L.P. post-transaction position
Indirect holdings
969,218 shares
Held by Third Rock Ventures VI, L.P.
Rule 10b5-1 plan date
November 21, 2025
Plan governing the reported sales
Key Terms
Rule 10b5-1 trading plan, weighted average price, beneficial ownership, pecuniary interest, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 21, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership regulatory
"disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein"
Section 13(d) "group" regulatory
"disclaims the existence of a Section 13(d) "group" as between any TRV V related parties and any TRV VI related parties"
FAQ
What did Third Rock Ventures report in its latest Form 4 for RAPP?
Third Rock Ventures V, L.P. reported selling 133,618 shares of Rapport Therapeutics common stock on May 11, 2026 at a weighted average price of $40.244 per share, executed as multiple trades within a narrow price range.
What price details are disclosed for the Third Rock sale of RAPP stock?
The Form 4 reports a weighted average sale price of $40.244 per share. It notes the shares were sold in multiple transactions, with individual sale prices ranging from $40.00 to $40.665, and offers to provide full breakdowns upon request.